198281-55-9

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-METHYL-PIPERAZIN-1-YLMETHYL)-ANILINE is used as a chemical intermediate for the preparation of pyrido[3,4-d]pyrimidin-4-ol derivatives. These derivatives have been identified as histone demethylase inhibitors, which play a crucial role in the regulation of gene expression and have potential applications in the treatment of various diseases, including cancer.
Used in the Synthesis of Histone Demethylase Inhibitors:
3-(4-METHYL-PIPERAZIN-1-YLMETHYL)-ANILINE is used as a building block in the development of novel histone demethylase inhibitors. These inhibitors can modulate the activity of histone demethylases, which are enzymes that remove methyl groups from histone proteins, thereby affecting gene expression. By targeting these enzymes, histone demethylase inhibitors may offer therapeutic benefits in the treatment of diseases with aberrant epigenetic regulation, such as cancer.

Upstream product

• 1015484-22-6 1-methyl-4-((trifluoro-λ⁴-boranyl)methyl)piperazine potassium 
• 108-42-9 3-chloro-aniline 
• 3958-57-4 1-bromomethyl-3-nitrobenzene 
• 109-01-3 1-methyl-piperazine 
• 99-61-6 3-nitro-benzaldehyde 
• 619-23-8 3-Nitrobenzyl chloride 
• 198281-54-8 1-methyl-4-(3-nitro-benzyl)-piperazine 

Downstream Products

• 503183-26-4 4-{[3-((4-methylpiperazin-1-yl)methyl)phenyl]hydrazono}-4H-pyrazole-3,5-diamine 
• 943189-22-8 N-methyl-N'-[3-(4-methylpiperazin-1-ylmethyl)phenyl]pyrimidine-4,6-diamine 
• 1350443-59-2 4-(4-methylpiperazin-1-ylmethyl)-N-[3-(4-methylpiperazin-1-ylmethyl)phenyl]benzamide 
• 1429617-80-0 C₂₈H₂₈N₆O 
• 1371209-21-0 C₂₀H₂₄N₄O₃ 

Relevant academic research and scientific papers

Methylpyrazole derivatives as RET inhibitor

The invention relates to a methylpyrazole derivative as an RET inhibitor, in particular to a compound as shown in a formula (I), a stereoisomer and pharmaceutically acceptable salt thereof, a preparation method and a pharmaceutical composition thereof. The compound of the formula (I) can be used for preventing or treating diseases mediated by abnormal RET activity.

HISTONE DEMETHYLASE INHIBITORS

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to novel pyrimide derivatives of formula (I): that are useful as kinase inhibitors. More particularly, the present invention relates to novel pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders.

Synthesis of new amides of the N-methylpiperazine series

New carboxylic acid amides containing an N-methylpiperazine fragment were synthesized by reactions of 1-methylpiperazine or 3- and 4-(4-methylpiperazin-1- ylmethyl)aniline with 4-chlorobenzoyl chloride and of 4-methyl-3-nitroaniline with 4-(4-methylpiperazin-1-ylmethyl)benzoyl chloride or benzotriazol-1-yl 4-(4-methylpiperazin-1-ylmethyl)benzoate. 4-Chloro-N-[4-(4-methylpiperazin-1- ylmethyl)phenyl]benzamide reacted with imidazole, quinolin-5-amine, and 2-methylquinolin-5-amine to give substituted 4-amino-N-[4-(4- methylpiperazin-1-ylmethyl)phenyl]benzamides. 4-Methyl-3-nitrophenyl-4- methylpiperazin-1-yl-substituted benzamides were reduced with hydrazine hydrate over Raney nickel to obtain N-(3-amino-4-methylphenyl)-4- (4-methylpiperazin-1- ylmethyl)benzamide as key intermediate in the synthesis of antileukemic agent imatinib and its isomer with alternative position of the amide group, 4-[(3-amino-4-methylphenylamino)methyl]phenyl- (4-methylpiperazin-1-yl)} methanone. Pleiades Publishing, Ltd., 2011.

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl- piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase

A novel series of N-aryl-N′-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the b

Aminomethylation via cyclopalladated-ferrocenylimine-complexes-catalyzed Suzuki-Miyaura coupling of aryl halides with potassium N, N - dialkylaminomethyltrifluoroborates

Using cyclopalladated ferrocenylimine complexes (1-3 mol%) as catalysts, the Suzuki-Miyaura coupling of potassium N,N-dialkylaminomethyltrifluoroborates with aryl and heteroaryl halides were carried out in a 10:1 THF-H2O mixture at 80° in the presence of Cs2CO3 (3.0 equiv) as base, giving the desired cross-coupling products in 14-87% yields. A variety of potassium alkyltrifluoroborates were also examined. Georg Thieme Verlag Stuttgart New York.

5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase

The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: W, A, Y, Z, R101 and R200 are described in the specification.

PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS

The invention relates to heteroaryl aryl ureas of the formula (IA), wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

Amide derivatives

The invention concerns amide derivatives of the Formula I wherein X is CH or N; Y is CH or N; m is 0-3; R1is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; n is 0-3; R2is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and (1-6C)alkoxycarbonyl; R3is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy; q is 0-4; and Q is a group such as aryl, aryloxy, aryl-(1-6C)alkoxy, arylamino,N-(1-6C)alkyl-arylamino and aryl-(1-6C)alkylamino; or pharmaceutically-acceptable salts or in-vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.